摘要
目的 了解中国卵巢癌临床诊疗现状,明确医生和患者的未满足需求,进一步规范中国卵巢癌的诊疗水平。方法 2023年全国30个省份共571名医生和1270例患者参与了调研。问卷内容主要包括患者病理类型、治疗方式、基因检测、手术情况、维持治疗和药物选择情况等。结果 共有427名医生和1158例患者完成了问卷。将2022和2023年调研问卷进行比较后发现,初始治疗后97%的患者接受辅助化疗,较2022年增长4%。96%的医生推荐BRCA1/2基因检测指导治疗,接受BRCA1/2基因检测的患者比例达75%,较2022年增长4%。随着药物可及性的提高和对药物疗效的认可,患者对于维持治疗的需求逐步提高,调研患者人群中正在接受维持治疗的患者比例为63%,较2022年提高10%。未受到医生建议维持治疗的患者中有52%愿意主动尝试维持治疗。若BRCA-患者的中位无进展生存期(PFS)达12个月,有76%的医生认为维持治疗具有必要性;若BRCA-/同源重组缺陷(HRD)-患者中位PFS达到9个月,有73%的医生认为维持治疗具有必要性,表明在BRCA-患者人群中,维持治疗的疗效已逐步得到医生认可。结论 调研结果反映了中国卵巢癌诊疗现状,主要关注了卵巢癌患者的BRCA1/2基因检测情况、患者主要的治疗方式、医生推荐和患者选择的维持治疗方案等,为中国卵巢癌规范化诊疗提供了参考意见。
Objective To investigate the current clinical diagnosis and treatment status of ovarian cancer in China,identify unmet needs among healthcare professionals and patients,and further standardize the level of ovarian cancer diagnosis and treatment in China.Methods In 2023,a nationwide survey was conducted,involving 571 doctors and 1270 patients from 30 provinces in China.The survey questionnaire primarily covered patient pathology types,treatment modalities,genetic testing,surgical procedures,maintenance therapy,and medication preferences.Results A total of 427 doctors and 1158 patients completed the survey.A comparative analysis between the 2022 and 2023 survey questionnaires revealed that after initial treatment,97%of patients received adjuvant chemotherapy,representing a 4%increase from 2022.Moreover,96%of doctors rec⁃ommended BRCA1/2 testing to guide treatment,with 75%of patients undergoing BRCA gene testing,marking a 4%increase from 2022.With the increased availability of medications and recognition of their efficacy,there has been a gradual rise in patient's demand for maintenance therapy.The proportion of patients in the surveyed population who were actively undergoing maintenance therapy was 63%,repre⁃senting a 10%growth from 2022.Among patients not initially advised by doctors to unergo maintenance therapy,52%ex⁃pressed a willingness to receive this treatment.If BRCA-patients achieved a median progression-free survival(PFS)of 12 months,76%of doctors considered maintenance therapy necessary,and if BRCA-/HRD-patients achieved a median PFS of 9 months,73%of doctors believed maintenance therapy to be essential,indicating that the effectiveness of mainte⁃nance therapy was gradually gaining recognition among physicians in the treatment of BRCA-patients.Conclusion The findings of this research reflect the current state of ovarian cancer diagnosis and treatment in China.The study primarily focuses on aspects such as BRCA1/2 genetic testing among ovarian cancer patients,their primary treatment modalities,and
作者
李璡
温灏
刘淑娟
邹冬玲
李俊东
王静
朱笕青
孙力
吴小华
LI Jin;WEN Hao;LIU Shu-juan;ZOU Dong-ling;LI Jun-dong;WANG Jing;ZHU Jian-qing;SUN Li;WU Xiao-hua(Department of Gynecology Oncology,Fudan University Shanghai Cancer Center,Department of Oncology,Shanghai Medical College,Fu-dan University,Shanghai 200032,China;Department of Obstetrics and Gynecology,Xijing Hospital,Air Force Medical University,Xi'an 710032,China;Department of Gynecology,Chongqing University Affiliated Cancer Hospital,Chongq-ing 400030,China;Department of Gynecology,Cancer Prevention and Treatment Center,Sun Yat-sen University,Guangzhou 510060,China;Department of Gynecology,Hunan Provincial Cancer Hospital,Changsha 410013,China;Department of Gynecology,Cancer Hospital of the University of Chinese Academy of Sciences,Hangzhou 310022,China;Department of Gynecology,Shenzhen Hospital,Chinese Academy of Medical Sciences,Shenzhen 518117,China)
出处
《中国实用妇科与产科杂志》
CAS
CSCD
北大核心
2023年第12期1225-1232,共8页
Chinese Journal of Practical Gynecology and Obstetrics
关键词
卵巢癌
诊断
治疗
维持治疗
白皮书
ovarian cancer
diagnosis
treatment
maintenance therapy
white paper
